Marie R. Griffin, United States of America
Vanderbilt University Medical Center PediatricsAuthor Of 4 Presentations
ADULT ALL-CAUSE AND PNEUMOCOCCAL PARAPNEUMONIC EMPYEMA HOSPITALIZATION RATES IN THE ERA OF DECLINING INVASIVE PNEUMOCOCCAL DISEASE AFTER PCVS INTRODUCTION IN THE US (ID 1176)
Abstract
Background
Parapneumonic empyema, a severe pneumonia complication, increased among US adults (especially older adults) after the introduction of 7-valent pneumococcal conjugate vaccine (PCV7), though the trend since PCV13 introduction remains unclear. We examined parapneumonic and pneumococcal empyema hospitalization rates among US adults during the PCVs era.
Methods
National Inpatient Sample and Census Data were used to calculate national annual all-cause and pneumococcal parapneumonic empyema hospitalization rates among adults. Rates were compared to national invasive pneumococcal disease (IPD) estimates from the CDC Active Bacterial Core surveillance system (1997-2017). We examined age-specific rates by vaccine era [pre-PCV7 (1997-1999); PCV7 (2001-2009); early-PCV13 era (2011-2015); and late-PCV13 (2016-2017) after transition from ICD9 to ICD10 codes].
Results
All-cause parapneumonic empyema hospitalization rates increased in every adult age group during the study period (Table). Pneumococcal parapneumonic empyema hospitalization rates followed similar trends as overall IPD and declined in every age group after PCV13 introduction (Figure). Modest increases were observed after PCV13 introduction for streptococcal parapneumonic empyema and parapneumonic empyema without an identified causative organism.
Conclusions
While the rate of all-cause parapneumonic empyema hospitalizations among US adults has increased in the last 2 decades, modest changes have been observed in pneumococcal parapneumonic empyema with declines following PCV13 introduction.
PNEUMOCOCCAL COLONIZATION DENSITY PATTERNS OVER TIME IN YOUNG CHILDREN IN THE PERUVIAN ANDES (ID 246)
- Leigh Howard, United States of America
- Kathryn M. Edwards, United States of America
- Marie R. Griffin, United States of America
- Yuwei Zhu, United States of America
- Jorge E. Vidal, United States of America
- Keith P. Klugman, United States of America
- Ana I. Gil, Peru
- Nicole R. Soper, United States of America
- Isaac P. Thomsen, United States of America
- Claudio F. Lanata, Peru
- Carlos Grijalva, United States of America
Abstract
Background
Factors associated with nasopharyngeal pneumococcal colonization density have not been comprehensively characterized. Age, immunization status, geographical location, population density, season, and/or acute respiratory illness (ARI) may play a role. We assessed longitudinal colonization density patterns in young rural Peruvian children.
Methods
Nasopharyngeal samples were collected monthly from children aged <3 years followed prospectively each week for ARI from May 2009-September 2011. PCV7 was introduced in the region in 2009. Longitudinally-collected samples from a convenience sample of children with >=1 pneumococcus-positive sample underwent density assessment by lytA qPCR. Density values were log10-transformed to reduce skewness. Assessments were stratified by enrollment age.
Results
Pneumococcus was detected in 471/625 (75%) samples from 30 children; 20/30 (67%) were enrolled before age 1. Variability was observed in colonization densities by calendar quarter and enrollment age, with substantial overlap in density levels and trajectories over time among age groups (Figure). Median densities during ARI episodes (n=62) were 5.60 (IQR 4.36-6.24) compared to non-ARI periods (5.00 [3.98-5.93], n=409, p=0.023).
Conclusions
Among these children, density varied by ARI status but did not clearly decrease with age. Future trajectory analyses will assess serotype-specific density colonization patterns and the association of serotype co-colonization, vaccination, and ARI status with pneumococcal density over time.
SUSTAINED IMPACT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE INTRODUCTION ON HOSPITALIZATIONS WITH ALL-CAUSE AND PNEUMOCOCCAL PARAPNEUMONIC EMPYEMA AMONG US CHILDREN (ID 421)
Abstract
Background
Parapneumonic empyema, a severe pneumonia complication, decreased shortly after 13-valent pneumococcal conjugate vaccine (PCV13) introduction among young US children but not among older children. We assessed the long-term impact of PCV13 introduction among US children encompassing the transition to the ICD10 coding system.
Methods
We used the National Inpatient Sample and Census Data to calculate national annual all-cause and pneumococcal parapneumonic empyema hospitalization rates among children <18 years (1997-2017). We examined rates during the late PCV13 era (2016-2017) after transition to ICD10 codes compared to pre-PCV7 (1997-1999), PCV7 (2001-2009) and early-PCV13 era (2011-2015) rates. We also examined changes in thoracentesis-related procedures.
Results
All-cause and pneumococcal parapneumonic empyema, as well as thoracentesis-related procedure rates reached historical lows in the late PCV13 era (Table). After initial declines following PCV13 introduction, rates have remained relatively stable (Figure). Modest, mostly downward, fluctuations were noted post-ICD10 transition.
Conclusions
Parapneumonic empyema rates in US children increased following PCV7 introduction but decreased and reached historic lows following PCV13 introduction. The change in coding from ICD9 to ICD10 did not appear to influence trends, though further assessment is warranted. Our findings support the ongoing surveillance of all-cause and pneumococcal empyema in the ICD10 coding era.
EVOLVING RISK PROFILE OF PATIENTS WITH INVASIVE PNEUMOCOCCAL DISEASE DURING THE PNEUMOCOCCAL CONJUGATE VACCINE ERA (ID 1144)
Abstract
Background
The incidence of invasive pneumococcal disease (IPD) due to serotypes covered by pneumococcal conjugate vaccines (PCVs) has declined since PCVs introduction. Whether the risk profile of IPD cases have changed following PCVs introduction is unclear.
Methods
We examined the comorbidity profile of all laboratory-confirmed IPD cases identified in Tennessee through active population and laboratory-based surveillance (1998-2017). Comorbidities were identified through chart review, and classified as high-risk and at-risk, as previously described (Figure). We examined changes in the proportion of patients with relevant comorbidities over time, and stratified estimates according to serotype information.
Results
The proportion of IPD cases with high-risk and at-risk comorbidities increased over time from 9% (1998-1999) to 26% (2016-2017) and from 22% to 59%, respectively. For IPD caused by vaccine-covered serotypes (PCV7 or those only covered by PCV13), increases in comorbidities prevalence were attenuated during recent years, but estimates’ precision was limited. For IPD caused by serotypes not in PCV13, the prevalence of comorbidities increased continuously (Figure).
Conclusions
After widespread use of PCVs, patients with residual IPD in Tennessee have a higher prevalence of relevant comorbidities than in previous years. These risk profile changes need to be considered in future prevention plans.